[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334199-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334199-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","human-papillomavirus-e6-alters-toll-like-receptor-9-transcripts-and-chemotherapy-responses-in-breast-cancer-cells-in-vitro","Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro","","Study investigates how human papillomavirus (HPV)16 E6 affects Toll-like receptor 9 (TLR9) regulation and chemotherapy-related phenotypes in breast cancer. Background notes that TLR9 is a DNA-recognizing receptor and that reduced TLR9 expression correlates with worse prognosis in triple negative breast cancer, yet its role remains unclear. Experiments transduce breast cancer cell lines with HPV16 E6, assess TLR9 mRNA/protein, proliferation, migration, invasion, and drug sensitivity in vitro, and analyze patient specimens for HPV DNA.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/human-papillomavirus-e6-alters-toll-like-receptor-9-transcripts-and-chemotherapy-responses-in-breast-cancer-cells-in-vitro/334199/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/human-papillomavirus-e6-alters-toll-like-receptor-9-transcripts-and-chemotherapy-responses-in-breast-cancer-cells-in-vitro/334199.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What hypothesis does the study test regarding HPV16 and TLR9?","Question",{"text":63,"@type":64},"The study tests whether HPV16 can suppress TLR9 expression in breast cancer cells and thereby affect cell behavior, including responses to chemotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the breast cancer cell experiments performed?",{"text":68,"@type":64},"Human T-47D and MDA-MB-231 breast cancer cells were transduced with lentivirus encoding the HPV16 E6 oncoprotein. Effects on TLR9 mRNA/protein and on proliferation, migration, invasion, and chemotherapy sensitivity were evaluated in vitro.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings about chemotherapy responses?",{"text":72,"@type":64},"E6 expression decreased TLR9 mRNA expression under hypoxia and significantly reduced sensitivity of breast cancer cells to the growth-inhibitory effects of multiple chemotherapeutic agents.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334199,1790187495,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Molecular Biology Reports (2025) 52:43  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1033-024-10143-1  \nORIGINAL ARTICLE  \nHuman papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro  \nEssi Parviainen1,2 · Sini Nurmenniemi1,2 · Sara Ravaioli3 · Sara Bravaccini3,4 · Aki Manninen5 · Arja Jukkola6,7 · Katri Selander1,8  \nReceived: 4 September 2024 / Accepted: 26 November 2024 / Published online: 7 December 2024 © The Author(s) 2024  \nAbstract  \nBackground Toll-like receptor 9 (TLR9) is a DNA recognizing receptor expressed also in several cancers. Decreased TLR9 expression is associated with poor prognosis in triple negative breast cancer (TNBC), but the role ofTLR9 in breast cancer pathophysiology is currently unclear. Regulation ofTLR9 expression in breast cancer is poorly understood. Human papillomavirus (HPV) infections suppress TLR9 expression in cervical cancers but the association between HPV and breast cancer has remained controversial. The aim of this study was to test if HPV16 can suppress TLR9 expression in breast cancer cells and affect cell behavior.  \nMethods and results Human T-47D and MDA-MB-231 breast cancer cells were transduced with lentivirus encoding HPV16 E6 oncoprotein. The effects of E6 on TLR9 mRNA and protein expression, and cell proliferation, migration, invasion and sensitivity to chemotherapy were studied in vitro. Breast cancer tissue samples (n = 37) were analyzed for the presence of HPV DNA. E6 expression decreased TLR9 mRNA expression in MDA-MB-231 and T-47D cells in hypoxia. E6 expression altered breast cancer cell proliferation and made cells significantly less sensitive to the growth inhibitory effects of chemotherapeutic agents. HPV L1 gene was not detected in a small pilot cohort of clinical breast cancer specimens.  \nConclusion HPV16 may influence breast cancer cell TLR9 transcription and chemotherapy responses and could thereby affect breast cancer prognosis. These results suggest that HPV may have a previously unrecognized role in breast cancer pathophysiology and warrant further studies on the topic.  \nKeywords Breast cancer · Toll-like receptor 9 · Human papillomavirus · Oncoprotein E6 · Chemotherapy · Cellular biology  \nAbbreviations  \nTLR9 Toll-like receptor 9 HPV Human papillomavirus mRNA Messenger RNA  \nE6 Early protein 6  \n􀀍 Sini Nurmenniemi [sini.nurmenniemi@oulu.fi](sini.nurmenniemi@oulu.fi)  \n1 Research Unit of Translational Medicine, University of Oulu, Oulu, Finland  \n2 Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland  \n3 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)“Dino Amadori”, Meldola, Italy  \n4 Faculty of Medicine and Surgery,“Kore” University of Enna, Enna, Italy  \nL1 Human papillomavirus major capsid protein  \nER Estrogen receptor  \nPR Progesterone receptor  \nHER2 Human epidermal growth factor receptor 2 TNBC Triple negative breast cancer  \n5 Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Oulu, Finland  \n6 Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland  \n7 Faculty of Medicine and Health Technology, Tampere Cancer Center, Tampere University, Tampere, Finland  \n8 Department of Oncology and Radiation Therapy, Oulu University Hospital, Oulu, Finland  \nGAPDH Glyceraldehyde-3-phosphate dehydrogenase  \nGFP Green fluorescent protein  \nHSCC Hypopharyngeal squamous cell carcinoma  \nSEM Standard error of the mean  \nIntroduction  \nBreast cancer is the most common cancer among women. During the year 2020, over 2.3 million new breast cancer cases and over 680 000 breast cancer deaths were reported worldwide [1] . Despite comprehensive screenings and effective treatments, the incidence is increasing especially in low-resource countries. Gender, aging, and genetic background are the main risk factors. Other intrinsic risk factors are early menarche, late","cbCaim7ai478PBfr","https://ap.wps.com/l/cbCaim7ai478PBfr","pdf",4178039,12,"English","# Abstract\n## Background\n## Methods and results\n## Conclusion\n# Introduction\n## Breast cancer burden and risk factors\n## Molecular subtype classification and treatment gaps\n## TLR9 biology and evidence in breast cancer\n# Keywords\n## Abbreviations","[{\"question\":\"What hypothesis does the study test regarding HPV16 and TLR9?\",\"answer\":\"The study tests whether HPV16 can suppress TLR9 expression in breast cancer cells and thereby affect cell behavior, including responses to chemotherapy.\"},{\"question\":\"How were the breast cancer cell experiments performed?\",\"answer\":\"Human T-47D and MDA-MB-231 breast cancer cells were transduced with lentivirus encoding the HPV16 E6 oncoprotein. Effects on TLR9 mRNA/protein and on proliferation, migration, invasion, and chemotherapy sensitivity were evaluated in vitro.\"},{\"question\":\"What were the main findings about chemotherapy responses?\",\"answer\":\"E6 expression decreased TLR9 mRNA expression under hypoxia and significantly reduced sensitivity of breast cancer cells to the growth-inhibitory effects of multiple chemotherapeutic agents.\"}]","Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro | PDF",1790005756]